Bernard Lerer

35.8k total citations · 1 hit paper
339 papers, 12.6k citations indexed

About

Bernard Lerer is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Bernard Lerer has authored 339 papers receiving a total of 12.6k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Psychiatry and Mental health, 77 papers in Cellular and Molecular Neuroscience and 76 papers in Molecular Biology. Recurrent topics in Bernard Lerer's work include Electroconvulsive Therapy Studies (68 papers), Bipolar Disorder and Treatment (66 papers) and Treatment of Major Depression (57 papers). Bernard Lerer is often cited by papers focused on Electroconvulsive Therapy Studies (68 papers), Bipolar Disorder and Treatment (66 papers) and Treatment of Major Depression (57 papers). Bernard Lerer collaborates with scholars based in Israel, United States and Germany. Bernard Lerer's co-authors include Michael E. Newman, Baruch Shapira, Bracha Shapira, Kyra Kanyas, Ronnen H. Segman, Richard P. Ebstein, Yoav Kohn, Dieter B. Wildenauer, Eitan Gur and Margot Albus and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Bernard Lerer

336 papers receiving 12.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression

2008 720 citations Bernard Lerer et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bernard Lerer	4.3k	2.9k	2.8k	2.6k	1.9k	339	12.6k
Robert H. Belmaker	4.5k 1.1×	3.1k 1.1×	2.7k 1.0×	1.6k 0.6×	1.1k 0.6×	291	13.0k
John I. Nürnberger	4.8k 1.1×	4.1k 1.4×	3.8k 1.3×	4.1k 1.6×	1.4k 0.8×	388	19.4k
Wagner F. Gattaz	6.1k 1.4×	2.1k 0.7×	2.5k 0.9×	1.1k 0.4×	1.3k 0.7×	387	14.5k
Hiroshi Kunugi	2.9k 0.7×	3.3k 1.1×	4.2k 1.5×	2.0k 0.8×	1.0k 0.5×	446	15.7k
Enrico Smeraldi	7.2k 1.7×	3.5k 1.2×	2.1k 0.8×	1.6k 0.6×	2.6k 1.4×	390	15.9k
Dan Rujescu	2.6k 0.6×	2.2k 0.8×	3.1k 1.1×	2.2k 0.9×	774 0.4×	347	11.4k
Julien Mendlewicz	4.7k 1.1×	1.7k 0.6×	1.2k 0.4×	1.5k 0.6×	3.0k 1.6×	386	13.1k
Armin Heils	2.4k 0.6×	5.5k 1.9×	3.1k 1.1×	1.3k 0.5×	904 0.5×	63	10.8k
Todd D. Gould	3.9k 0.9×	4.8k 1.7×	3.5k 1.2×	2.3k 0.9×	3.6k 1.9×	141	15.6k
Nakao Iwata	3.0k 0.7×	3.0k 1.0×	3.3k 1.2×	2.1k 0.8×	1.5k 0.8×	482	11.4k

Countries citing papers authored by Bernard Lerer

Since Specialization

Citations

This map shows the geographic impact of Bernard Lerer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernard Lerer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernard Lerer more than expected).

Fields of papers citing papers by Bernard Lerer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernard Lerer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernard Lerer. The network helps show where Bernard Lerer may publish in the future.

Co-authorship network of co-authors of Bernard Lerer

This figure shows the co-authorship network connecting the top 25 collaborators of Bernard Lerer. A scholar is included among the top collaborators of Bernard Lerer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernard Lerer. Bernard Lerer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lifschytz, Tzuri, et al.. (2025). Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration. Translational Psychiatry. 15(1). 200–200. 1 indexed citations

Lifschytz, Tzuri, et al.. (2025). Premorbid characteristics of the SAPAP3 mouse model of obsessive-compulsive disorder: behavior, neuroplasticity, and psilocybin treatment. The International Journal of Neuropsychopharmacology. 28(5). 1 indexed citations

Lifschytz, Tzuri, et al.. (2024). Exploring the potential of synergistic psychedelic – NMDAr modulator treatment for refractory neuropsychiatric disorders. Neuroscience Applied. 3. 103975–103975.

Lerer, Elad, Alex Buko, Karin Blakolmer, et al.. (2024). Effect of chemically synthesized psilocybin and psychedelic mushroom extract on molecular and metabolic profiles in mouse brain. Molecular Psychiatry. 29(7). 2059–2073. 15 indexed citations

Heresco‐Levy, Uriel & Bernard Lerer. (2023). Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Molecular Psychiatry. 29(1). 146–152. 9 indexed citations

Singh, Sandeep, et al.. (2023). Effect of psilocybin on marble burying in ICR mice: role of 5-HT1A receptors and implications for the treatment of obsessive-compulsive disorder. Translational Psychiatry. 13(1). 164–164. 33 indexed citations

Lotan, Amit, et al.. (2022). Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. International Journal of Molecular Sciences. 23(22). 14148–14148. 35 indexed citations

Wolf, Gilly, Sandeep Singh, Karin Blakolmer, et al.. (2022). Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Molecular Psychiatry. 28(1). 44–58. 24 indexed citations

Lifschytz, Tzuri, Santanu Mondal, Aviva Katzav, et al.. (2021). Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene. 40(44). 6248–6257. 9 indexed citations

10.

Taliaz, Dekel, Amit Spinrad, Ran Barzilay, et al.. (2021). Optimizing prediction of response to antidepressant medications using machine learning and integrated genetic, clinical, and demographic data. Translational Psychiatry. 11(1). 381–381. 58 indexed citations

11.

Lifschytz, Tzuri, et al.. (2021). Evaluation of the Therapeutic Potential of Oral Phycocyanin-Rich SpirulinaExtracts in Neuropsychiatric Disorders. The Natural Products Journal. 12(6). 1 indexed citations

12.

Katzav, Aviva, Debora Kidron, E. L. Edelstein, et al.. (2020). DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer Letters. 501. 224–233. 13 indexed citations

13.

Lifschytz, Tzuri, Gilly Wolf, Amihai Rigbi, et al.. (2019). White matter lesions, cerebral inflammation and cognitive function in a mouse model of cerebral hypoperfusion. Brain Research. 1711. 193–201. 30 indexed citations

14.

Constantini, Naama, et al.. (2015). Effectiveness of Aerobic Exercise as an Augmentation Therapy for Inpatients with Major Depressive Disorder: A Preliminary Randomized Controlled Trial.. PubMed. 52(3). 65–70. 6 indexed citations

15.

Kohn, Yoav, Nanette Freedman, Hava Lester, et al.. (2008). Cerebral perfusion after a 2-year remission in major depression. The International Journal of Neuropsychopharmacology. 11(6). 837–43. 7 indexed citations

16.

Stein, Dan J., Bernard Lerer, & Stephen M. Stahl. (2005). Evidence-based psychopharmacology. Cambridge University Press eBooks. 18 indexed citations

17.

Lerer, Bernard & Fabìo Macciardi. (2002). Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. The International Journal of Neuropsychopharmacology. 5(3). 255–75. 65 indexed citations

18.

Lerer, Bernard & Julien Mendlewicz. (2000). Vaeiability of 5-HT2C receptor CYS23SER polymorphism in European populations and vulnerability to affective disorder. American Journal of Medical Genetics Part A. 96(4). 484. 1 indexed citations

19.

Shapira, Baruch, et al.. (1999). Social adjustment and self-esteem in remitted patients with unipolar and bipolar affective disorder: A case-control study. Comprehensive Psychiatry. 40(1). 24–30. 44 indexed citations

20.

Ebstein, Richard P., et al.. (1988). Lithium modulation of second messenger signal amplification in man: Inhibition of phosphatidylinositol- specific phospholipase C and adenylate cyclase activity. Psychiatry Research. 24(1). 45–52. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact